Published in J Biol Chem on May 05, 2017
The hallmarks of cancer. Cell (2000) 113.05
The functions of animal microRNAs. Nature (2004) 64.85
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 23.55
Long noncoding RNA as modular scaffold of histone modification complexes. Science (2010) 15.23
Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol (2008) 12.35
A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell (2010) 12.27
Non-coding RNAs in human disease. Nat Rev Genet (2011) 11.40
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene (2006) 6.61
The functional role of long non-coding RNA in human carcinomas. Mol Cancer (2011) 6.37
Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev (2000) 6.07
Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res (2011) 6.02
HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene (2012) 4.30
Large non-coding RNAs: missing links in cancer? Hum Mol Genet (2010) 3.49
Aberrations of EZH2 in cancer. Clin Cancer Res (2011) 3.13
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med (2001) 2.87
Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res (1999) 2.32
Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat Rev Mol Cell Biol (2008) 2.21
Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res (2007) 1.83
Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma. Oncol Rep (2012) 1.81
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene (2012) 1.75
Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res (2010) 1.64
Long Noncoding RNAs in Cancer Pathways. Cancer Cell (2016) 1.63
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol (2009) 1.51
Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ Res (2012) 1.45
Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm (2010) 1.43
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol (2012) 1.34
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther (2010) 1.34
Runx2-upregulated receptor activator of nuclear factor κB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol (2011) 1.34
A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res (2010) 1.26
Regulation of metabolism by long, non-coding RNAs. Front Genet (2014) 1.21
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer (2010) 1.19
Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett (2001) 1.11
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther (2012) 0.98
TRAIL: a sword for killing tumors. Curr Med Chem (2010) 0.96
Serum response factor regulates bone formation via IGF-1 and Runx2 signals. J Bone Miner Res (2012) 0.95
Activation of AKT by O-linked N-acetylglucosamine induces vascular calcification in diabetes mellitus. Circ Res (2014) 0.95
Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res (2001) 0.94
PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy. Clin Cancer Res (2013) 0.93
Photothermal Treatment of Human Pancreatic Cancer Using PEGylated Multi-Walled Carbon Nanotubes Induces Apoptosis by Triggering Mitochondrial Membrane Depolarization Mechanism. J Cancer (2014) 0.90
A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Eur J Cancer (2014) 0.90
MicroRNAs: miRRORS of health and disease. Transl Res (2011) 0.87
MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. Proc Natl Acad Sci U S A (2015) 0.87
Immunotherapy improves overall survival in pancreatic cancer. Lancet Oncol (2015) 0.82
The AS-RBM15 lncRNA enhances RBM15 protein translation during megakaryocyte differentiation. EMBO Rep (2016) 0.81
Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer. Oncotarget (2015) 0.81